Skip to main content Skip to navigation


Intended as an aid in the diagnosis of acute lymphoblastic leukemia and non-lymphoid acute leukemia



The BD OneFlow™ ALOT is part of the innovative BD OneFlow™ Solution, a comprehensive set of reagents, setup beads, protocols and assay templates to reproducibly set up the flow cytometer and stain, acquire and analyze patient specimens for immunophenotyping of normal and aberrant cell populations. It is built on the research and validation work of the EuroFlow™ Consortium on the characterization of hematological malignancies for improved accurate diagnosis.1*


The BD OneFlow™ ALOT is  intended for flow cytometric immunophenotyping of aberrant immature populations of hematopoietic cells (lymphoid and non-lymphoid lineage) in bone marrow and peripheral blood as an aid in the diagnosis of acute lymphoblastic leukemia and non-lymphoid acute leukemia.


Other reagents belonging to the BD OneFlow™ Solution are BD OneFlow™ Lymphoid Screening Tube (LST), BD OneFlow™ B-cell Chronic Lymphoproliferative Diseases Tube 1 (B-CLPD T1)BD OneFlow™ Plasma Cell Screening Tube (PCST)BD OneFlow™ Plasma Cell Disorders (PCD) Tube.



View video describing the BD OneFlow™ Solution on the BD FACSLyric™ Flow Cytometer. 



The BD OneFlow™ ALOT reagent composition


Antibody Fluorochrome Clone Tube Target Populations
MP0 FITC MP0-7 C Myeloid lineage marker


PE HM57 C B-lineage marker
CD34 PerCP-Cy 5.5 8G12 S Backbone marker (BCP-ALL and AML Panels).
Identification of immature cells.
CD19 PE-CY 7  SJ25-C1 S Backbone marker (BCP-ALL Panel).
B-lineage marker
CD7 APC M-T701 S T-lineage marker
CD3 APC-H7 SK7 S Backbone marker (T-ALL panel).
CD3 BD Horizon™ V450 UCHT-1 C Backbone marker (T-ALL panel).
Maturity marker for T-cells.
CD45 BD Horizon™ V500-C 2D1 S Backbone marker.
Identification of immature cells.


A full description of the utility of the antibodies chosen for the BD OneFlow™ ALOT is provided in the publication by the EuroFlow Consortium.1 





Supporting Evidence

An unprecedented orientation efficiency of 98.3% for non-ambiguous lineage cases was shown for the [EuroFlow] ALOT combination with a series of 483 newly diagnosed acute leukemia cases, tested prospectively at different centers.”1*


Results from the clinical trial (BD OneFlow™ ALOT Instruction For Use) showed that the BD OneFlow™ ALOT gave an overall agreement of 100% (93 of 93) in orienting patients into lymphoid (44 of 44 concordant) and non-lymphoid (49 of 49 concordant) lineages when compared with the EuroFlow system. Furthermore, interpretation of clinical trial results using the BD OneFlow™ Solution was highly concordant to diagnostic truth derived from a composite of patient history and lab findings.


  1. van Dongen JJM, Lhermitte L, Böttcher S, et al. on behalf of the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9): 1908-1975. doi: 10.1038/leu.2012.120

  2. Moloney E, Watson H, Barge D, et al. Efficiency and health economic evaluations of BD OneFlow™ Flow Cytometry Reagents for diagnosing chronic lymphoid leukemia. Cytometry B Clin Cytom. 2019;96(6):514-520. doi: 10.1002/cyto.b.21779

  3. Kalina T, Flores-Montero J, van der Velden VHJ, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010. doi: 10.1038/leu.2012.122

BD Flow Cytometers are Class 1 Laser Products.

The BD OneFlow™ Solution is intended for professional use only.

The EuroFlow trademark is the property of the EuroFlow Consortium and cannot be reproduced or published without prior written permission from the EuroFlow coordinator (

Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.

*This publication refers to EuroFlow and is relevant to the BD OneFlow™ Solution as the BD OneFlow™ Solution demonstrated equivalent results to EuroFlow through a clinical trial.